The Challenge of Anticoagulation in Liver Cirrhosis

Background: Advanced liver diseases are characterized by a number of changes in the hemostatic system. Due to the occurrence of bleeding events in patients with liver cirrhosis, there seems to be a hesitance to the administration of anticoagulant medications. This review summarizes challenges, recommendations, and current developments of anticoagulation in the cirrhotic patient. Summary: The risk of thrombotic events in patients with liver cirrhosis is at least as high as in patients with healthy liver function if not even higher. Standard laboratory markers do not truly reflect the complexity of changes that take place in the coagulative system and therefore cannot be used as a reference for risk of thrombosis or hemorrhage. Potential options for anticoagulant therapy are heparins, vitamin K antagonists, and direct-acting oral anticoagulants which come with differences in safety, application, possible side effects, and data availability for the patient cohort. Key Message: The administration of anticoagulation can be beneficial in patients with liver disease if the indication is present and bleeding prophylaxis has been established. Direct-acting oral anticoagulants appear to be a promising new approach with many improvements compared to conventional substances. Nevertheless, there is a need for further data and prospective trials on the use in patients with liver cirrhosis.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: The Challenge of Anticoagulation in Liver Cirrhosis ; volume:39 ; number:6 ; year:2023 ; pages:169-176 ; extent:8 ; Visceral medicine ; 39, Heft 6 (2023), 169-176 (gesamt 8)

Contributors, Places and Time

• Creator: Eichholz, Julia Carolin ; Wedemeyer, Heiner ; Maasoumy, Benjamin

Further information

• DOI: 10.1159/000535438
• URN: urn:nbn:de:101:1-2024011723161809196018
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 06.10.2038, 8:02 AM CEST